Protagonist Therapeutics shares are trading higher after BTIG maintained a Buy rating on the stock and raised its price target from $41 to $51.
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics shares are trading higher after BTIG maintained a Buy rating on the stock and raised its price target from $41 to $51.
July 24, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics shares are trading higher after BTIG maintained a Buy rating on the stock and raised its price target from $41 to $51.
The positive analyst rating and increased price target from a reputable firm like BTIG are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100